Arter et al. identified NTRK-positive and RET-positive CRC as distinct disease entities that could potentially respond to immunotherapy with agents such as pembrolizumab, dostarlimab, or nivolumab in combination with ipilimumab [16]. The gene discussed is RET; the disease is colorectal carcinoma.